ClinicalTrials.gg
CompletedNCT04827069Updated Sep 19, 2024

A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

A Phase 1 interventional study of Clifutinib Besylate in Acute Myeloid Leukemia, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled May 2018, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
156th of 433
75 · median 50
Started
2018
with 26 others
Phase 1
121 of 473
69 open now
Registered
131st of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 156th largest by enrollment of the 433 interventional ones that give a count, is one of 27 that started in 2018, is one of 121 in phase 1, and was the 131st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.

Read the detailed description

It is a multi-center , open-label, single arm study conducted in 2 parts. Dose-escalation part: Subjects will receive oral Clifutinib Besylate once on C0D1.After 3 days,they will receive Clifutinib Besylate once daily repeatedly until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days.

Expansion part:Expansion cohort might be set to further investigate the safety and efficacy of Clifutinib Besylate at or lower MTD dose recommended by dose-escalation part.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented acute myeloid leukemia according to World Health Organization(WHO) criteria(excluding acute promyelocytic leukemia), with FLT3-ITD gene mutation, after common or enhanced chemotherapy or relapse.
  • performance status of 0-1.
  • Subjects must have adequate organ function and meeting all of the following laboratory review before enrollment:

    • Lood routine examination: WBC≤2000/mm3;
    • Liver function: (ALT) and Aspartate transaminase (AST) ≤2.5×(ULN); serum ≤ 1.5 × ULN;
    • Renal function: Serum creatinine ≤ 1.5×ULN, or the (CrCl)≥ 60 mL / min calculated by the Cockcroft-Gault formula;
    • Electrolyte: serum potassium≥3.0mmol/L; serum calcium≥2.0 mmol/L;serum magnesium≥0.5 mmol/L;
    • Coagulation function:fibrinogen≥1.0g/L; ( APTT)≦ULN+10s; prothrombin time(PT)≤ULN+3s.

Exclusion criteria

Exclusion Criteria:

  • Received FLT3 inhibitors within 4 weeks prior to the administration;
  • Received hematopoietic stem cell transplantation within2 months prior to the administration or received immunosuppressor beceause of ;
  • Chemotherapy, immunotherapy, radiotherapy, or major surgery within 4 weeks prior to administration;
  • Nitrosourea and mitomycin chemotherapy within 6 weeks prior to the administration;
  • Have taken within 4 weeks prior to /or concurrent with the administration;
  • Have received a trial product, or participated in other clinical trials within 4 weeks prior to administration;
  • Documented promyelocytic leukemia (t (15; 17) (q22; q11) and / or promyelocytic leukemia(PML)/retinoic acid receptor alpha (RARa) positivity found in the chromosome, variant acute promyelocytic leukemia;
  • With myeloid sarcoma or invasion of central nervous system;
  • 4.03 ≥ 2 grade of arrhythmia, or interval(QTc )> 450 ms ; patients with a history of torsion or congenital QT prolonged syndrome; active infectious disease judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Arm 1

    Clifutinib Besylate:10 mg

    Drug: Clifutinib Besylate

  • Experimental
    Arm 2

    Clifutinib Besylate:20 mg

    Drug: Clifutinib Besylate

  • Experimental
    Arm 3

    Clifutinib Besylate:40 mg

    Drug: Clifutinib Besylate

  • Experimental
    Arm 4

    Clifutinib Besylate:55 mg

    Drug: Clifutinib Besylate

  • Experimental
    Arm 5

    Clifutinib Besylate:70 mg

    Drug: Clifutinib Besylate

  • Experimental
    Arm 6

    Clifutinib Besylate:100 mg

    Drug: Clifutinib Besylate

Interventions

  • DrugClifutinib Besylate

    receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

    Also known as: HEC73543

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Safety and Tolerability assessed through adverse events to determine maximum tolerated dose

    Time frame: day 1-28

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    to assess the pharmacokinetic profile in patients with AML

    Time frame: On day 1,8,15,22,28

  2. Time of maximum observed plasma concentration (Tmax)

    to assess the pharmacokinetic profile in patients with AML

    Time frame: On day 1,8,15,22,28

  3. Area under the plasma concentration time curve

    to assess the pharmacokinetic profile in patients with AML

    Time frame: On day 1,8,15,22,28

  4. Composite CR rate

    CR + CRi +CRMRD-

    Time frame: up to 18 months

  5. Duration of response

    The time from receive CR / CRi/CRMRD-/PR to relapse

    Time frame: up to 18 months

  6. Objective response rate

    CR + CRi +CRMRD- + PR

    Time frame: up to 18 months

  7. Event Free Survival

    From the first time taking experimental drug to treatment failure or progression or relapse or death

    Time frame: up to 18 months

  8. Overall Survival

    From the first time taking experimental drug to death

    Time frame: up to 18 months

07

Study locations

1 site
  • the First Affiliated Hospital,College of Medicine,Zhejiang University
    Hanzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Aug 2023, 63 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 63 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Apr 1, 2021
StartActual
May 18, 2018
Primary completionActual
Aug 21, 2023
CompletionActual
Aug 30, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04827069
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
May 18, 2018
Primary completion
Aug 21, 2023
Completion
Aug 30, 2023
Last update
Sep 19, 2024

Study contacts

Jie Jin, Doctor
study chair · First Affiliated Hospital of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion